Carrier screening is a form of genetic test that can determine whether you are a carrier of a gene for certain genetic illnesses. It allows you to figure out your odds of having a kid with a genetic condition before or during pregnancy.
Carrier screening is a testing procedure that determines whether or not a person has a gene for a genetic illness. Carrier screening is most commonly used before/during pregnancy to reduce the risk of illness transmission to the newborn. It is suggested that both parents undergo carrier screening, as the likelihood of passing on the genetic condition increases if both parents are carriers.
Rising mergers, agreements, and acquisitions by market players are expected to drive the global carrier screening market over the forecast period. For instance, in July 2017, Counsyl, Inc., entered into an expanded agreement with Angsana Molecular & Diagnostics Laboratory, a multinational laboratory services company, to commercialize expanded carrier screening (ECS) test in Hong Kong. Furthermore, in July 2018, Counsyl, Inc. was acquired by Myriad Genetics, Inc. The acquisition is expected to strengthen the genetic tests portfolio of Myriad Genetics, Inc.
Furthermore, numerous launches and approvals of new carrier screening tests are expected to drive carrier screening market growth throughout the forecast period. Invitae Corporation, for example, announced the debut of the Invitae Carrier Screen in June 2018, which is a test developed for better risk assessment to detect the possibility of the kid having a genetic condition.
Because of product approvals and the launch of novel carrier screening tests in the area, North America accounted for the greatest market share in 2018. For example, in October 2019, Sema4 announced the release of the Expanded Carrier Screen, a test that determines the chance of a kid developing an inherited genetic condition.
Europe is also witnessing lucrative growth in the carrier screening market owing to launches and approvals of new screening tests in the region. For instance, in June 2019, QIAGEN, a German provider of sample and assay technologies for molecular diagnostics, launched QIAseq Expanded Carrier Screening Panel. The QIAseq provides information about the targets and genes that are responsible for 200 disease indications.
No comments:
Post a Comment